Short-term preventive treatment with on-demand Berinert (human C1 esterase inhibitor) immediately before delivery helps women with hereditary angioedema (HAE) avoid swelling attacks during childbirth, according to case series and literature review from Japan. About half of pregnant women with HAE experienced more acute attacks during pregnancy, particularly in…
Ekterly (sebetralstat), given as a tablet that dissolves on the tongue, resulted in early, effective, and safe management of swelling attacks in children with hereditary angioedema (HAE) aged 2-11, according to interim data from a clinical trial. The ongoing Phase 3 study, KONFIDENT-KID (NCT06467084), which has enrolled…
Patient enrollment has been completed in a global Phase 3 clinical trial that’s evaluating lonvoguran ziclumeran, also known as lonvo-z (NTLA-2002), a gene-editing therapy Intellia Therapeutics is developing to prevent swelling attacks in people with hereditary angioedema (HAE). Dubbed HAELO (NCT06634420), the trial — which…
Pendopharm has obtained the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat, an on-demand investigational treatment for hereditary angioedema (HAE), in Canada under a licensing agreement with Kalvista Pharmaceuticals, the developer of the therapy. “We look forward to collaborating with Pendopharm, whose deep…
Oral deucrictibant continued to control swelling attacks as a preventative therapy and rapidly stop swelling attacks as an on-demand treatment for hereditary angioedema (HAE), according to new data from the open-label extension portions of two clinical trials. All open-label extension participants said that preventive deucrictibant controlled their HAE…
Kalvista Pharmaceuticals’ sebetralstat, an oral on-demand treatment for hereditary angioedema (HAE), rapidly stopped the progression of swelling attacks, according to interim data from a two-year open-label extension study. It was also effective against attacks involving the larynx (voice box) and abdomen, as well as those rated as severe or…
The U.S. Food and Drug Administration (FDA) has accepted Biocryst Pharmaceuticals’ application to approve an oral granule formulation of Orladeyo (berotralstat) for children with hereditary angioedema (HAE) as young as 2. The FDA granted the application priority review, which shortens the process from the standard 10 months…
Andembry (garadacimab), a first-in-class treatment to prevent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older, is now available in Japan. The treatment was approved by Japan’s Ministry of Health, Labour and Welfare in February, Andembry is the first prophylactic (preventive) therapy in Japan that…
Deucrictibant, an oral therapy being developed for bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema, has been granted orphan drug status in the European Union. This designation, granted by the European Commission, intends to back the development of therapies to diagnose, prevent, or treat rare…
Throughout 2024, Angioedema News brought our readers all the latest news and updates on clinical research and scientific advances related to the rare disease. Here are this year’s top 10 most-read articles on angioedema — many related to the prevention and treatment of swelling, the hallmark of the…
Get regular updates to your inbox.
